1
rich
Libsyn
https://www.libsyn.com
90
600
Age, BMI, & TAVR; Enhanced Radiation Protections in Cath Labs; Particulate Matter and CV Risk; the SUMMIT Trial & Tirzepatide.
In this week’s View, Dr. Eagle looks at age, body mass index (BMI), and cardiovascular outcomes after transcatheter aortic valve replacement (TAVR). He follows this with an examination of a new consensus statement about enhanced radiation protection in cath labs, then offers a perspective on particulate matter in the environment and increased coronary heart disease risk. Finally, Dr. Eagle provides an analysis of the SUMMIT Trial, showing the benefit of tirzepatide for heart failure with preserved ejection fraction (HFpEF) both in women and men.   Subscribe to Eagle’s Eye View  
Eagle's Eye View: Your Weekly CV Update From ACC.org
http://www.acc.org
<iframe title="Libsyn Player" style="border: none" src="//html5-player.libsyn.com/embed/episode/id/42171155/height/90/theme/custom/thumbnail/yes/direction/forward/render-playlist/no/custom-color/88AA3C/" height="90" width="600" scrolling="no" allowfullscreen webkitallowfullscreen mozallowfullscreen oallowfullscreen msallowfullscreen></iframe>
https://assets.libsyn.com/secure/content/204343370